Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P11 - Health Services Research/Health Economics - Quality of Life
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P11.01 - Exploring Patient Reported Quality of Life in Lung Cancer Patients: A Qualitative Study
00:00 - 00:00 | Presenter: Elena Jensen-Marini
- Abstract
Loading... -
+
P11.02 - Patient Reported Outcome Measures (PROM) after Thoracic Surgery: A Pilot Study
00:00 - 00:00 | Presenter: Jitian Zhang
- Abstract
Loading... -
+
P11.03 - Importance of Capturing the Patient Experience of Overall Symptoms and HRQoL Impact in Patients With ALK+ NSCLC
00:00 - 00:00 | Presenter: Yanyan Zhu
- Abstract
Loading...
-
+
P12 - Health Services Research/Health Economics - Health Policy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P12.01 - Pilot Training Program, Redesign of the Attention System and Time Reduction on Lung Cancer Patients in a Mexican Hospital
00:00 - 00:00 | Presenter: Saul Campos-Gomez
- Abstract
Loading... -
+
P12.02 - Implementation of a Timeliness-of-care Pathway System for Lung Cancer Patients in a Private Outpatient Oncology Service.
00:00 - 00:00 | Presenter: Iuri Amorim Santana
- Abstract
Loading... -
+
P12.03 - Public Versus Private Care Patients Treated in the Same Hospital. Are the Patients the Same?
00:00 - 00:00 | Presenter: Maria Teresa Ruiz Tsukazan
- Abstract
Loading... -
+
P12.04 - Access of Lung Cancer to High Technology Radiation Therapy in Brazil
00:00 - 00:00 | Presenter: LILIAN Faroni
- Abstract
Loading... -
+
P12.05 - Current State and Challenges of Lung Cancer Treatment in Georgia
00:00 - 00:00 | Presenter: Elene Mariamidze
- Abstract
Loading...
-
+
P13 - Health Services Research/Health Economics - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P13.01 - Analysis of the Effect of Personalized Nursing in Patients Undergoing Thoracoscopic Surgery for NSCLC
00:00 - 00:00 | Presenter: Yuanyong Wang
- Abstract
Loading... -
+
P13.02 - Role of Management Checklist in the Prevention and Control of NCP in Oncology Ward
00:00 - 00:00 | Presenter: Li Li
- Abstract
Loading... -
+
P13.03 - The Role of Nurse Practitioners Within Thoracic Radiation Oncology and the Benefit to Patients, Physicians and the Healthcare System
00:00 - 00:00 | Presenter: Ulrike Gorgens
- Abstract
Loading... -
+
P13.04 - Should We Offer Germline Testing to All Patients With Lung Cancer? An Ethical Point of View.
00:00 - 00:00 | Presenter: Guillermo Pacheco-Cuellar
- Abstract
Loading... -
+
P13.05 - Real-World Treatment Patterns and Sequencing of Immunotherapy and Chemotherapy Based on PD-L1 TPS in European Patients With mNSCLC
00:00 - 00:00 | Presenter: Megan N Gower
- Abstract
Loading...
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P14.01 - Impact of Stimulator of Interferon Genes (STING) Signaling on the Tumor Immune Microenvironment in Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Jiewei Liu
- Abstract
Loading... -
+
P14.02 - Expression and Significance of Indoleamine 2,3 Dioxygenase on Tumor Cell and Tumor Stroma Compartments of Lung Squamous Cell Carcinoma
00:00 - 00:00 | Presenter: Wei Wang
- Abstract
Loading... -
+
P14.03 - Histotype-dependent Associations of LAG-3 Expression with Clinicopathologic Features and Survival in Non-small Cell Lung Cancer
00:00 - 00:00 | Presenter: Dan Shepherd
- Abstract
Loading... -
+
P14.04 - cfRNA from Liquid Biopsies Is More Abundant Than cfDNA, Informs Treatment Outcome and Is Concordant with Tissue
00:00 - 00:00 | Presenter: Luis E. Raez
- Abstract
Loading... -
+
P14.05 - The Relationship Between Genomic Alterations and the Efficacy of Immune Check Point Inhibitor for KRAS Mutated Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Naoki Furuya
- Abstract
Loading... -
+
P14.06 - Dysregulation of m6a Reader IGF2BP1 in Lung Adenocarcinoma Affects the Immune Microenvironment and Indicates a Poor Recovery
00:00 - 00:00 | Presenter: Xuequan Wang
- Abstract
Loading... -
+
P14.07 - Clinically Predictive Value of Plasma Cell-Free DNA in Lung Cancer Immunotherapy
00:00 - 00:00 | Presenter: Lin Li
- Abstract
Loading... -
+
P14.09 - Early Expansion of M-MDSCs and High Plasma TSLP levels as Predictors of Primary Resistance to PD1 Inhibitors in Metastatic NSCLC
00:00 - 00:00 | Presenter: Sally Chui Mei Lau
- Abstract
Loading... -
+
P14.10 - Efficacy of Anti-PD-1/PD-L1 Monoclonal Antibody Treatment of Advanced NSCLC on Density and Distribution of Tumor Infiltrating T Cells
00:00 - 00:00 | Presenter: Yuanyong Wang
- Abstract
Loading... -
+
P14.11 - Optimal Combination of Biomarkers to Improve the Predictive Value of Immunotherapeutic Response in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Soohyeon Kwon
- Abstract
Loading... -
+
P14.12 - MET Amplification and Immune Checkpoint Inhibitor Efficacy in NSCLC
00:00 - 00:00 | Presenter: shan Su
- Abstract
Loading... -
+
P14.13 - Notch Family Gene Mutations Predict Clinical Benefit from Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Huaqiang Zhou
- Abstract
Loading... -
+
P14.14 - PTPRD: A Positive Predictive Biomarker for Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jiayi Shen
- Abstract
Loading... -
+
P14.15 - Circulating Tumor DNA Predict the Response and Survival after Tislelizumab Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma
00:00 - 00:00 | Presenter: qiong He
- Abstract
Loading... -
+
P14.16 - The Early Landscape of Immune Cell Subsets in Metastatic NSCLC Patients Treated with Immune Checkpoint Inhibitors
00:00 - 00:00 | Presenter: Jianguo Zhou
- Abstract
Loading... -
+
P14.17 - Low BMI is Associated with Inferior Overall Survival in HIV Patients with Advanced NSCLC Undergoing Immunotherapy
00:00 - 00:00 | Presenter: Emily Lin
- Abstract
Loading... -
+
P14.18 - Expression and Clinical Significance of CMTM6 in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Sisi He
- Abstract
Loading... -
+
P14.19 - CD8α-Enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1
00:00 - 00:00 | Presenter: Mehmet Altan
- Abstract
Loading... -
+
P14.20 - Multi-Spectral Imaging of Lung Adenocarcinoma Reveals Importance of Cancer Specific HLA-DR on the TME and Clinical Outcome
00:00 - 00:00 | Presenter: Erin L Schenk
- Abstract
Loading... -
+
P14.21 - Baseline Derived Neutrophil-to-Lymphocyte Ratio (dNLR) and Clinical Outcomes to First-Line Pembrolizumab in NSCLC with High PD-L1 (≥50%)
00:00 - 00:00 | Presenter: Joao Victor M. Alessi
- Abstract
Loading... -
+
P14.22 - Radiotherapy With Sequential αnti-PD-1 mAb Is Better in Enhancing the Abscopal Effect by Promoting the Inflammatory Tumor Microenvironment
00:00 - 00:00 | Presenter: Xiaoxia Zhu
- Abstract
Loading... -
+
P14.23 - Different in Situ Immune Pattern Between Primary Tumor and Metastatic Lymph Node in NSCLC: Potential Impact on Neoadjuvant Immunotherapy
00:00 - 00:00 | Presenter: Ze-Rui Zhao
- Abstract
Loading... -
+
P14.24 - Evolution of TCR Clonality during Chemoradiation and Durvalumab as Predictors of Survival in Stage 3 NSCLC
00:00 - 00:00 | Presenter: Sally Chui Mei Lau
- Abstract
Loading... -
+
P14.25 - Immune Cell Profiling of Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Antibodies
00:00 - 00:00 | Presenter: Kyung Hwan Kim
- Abstract
Loading... -
+
P14.26 - Diminished Efficacy of PD-(L)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma is Impacted by KRAS Mutation Status
00:00 - 00:00 | Presenter: Biagio Ricciuti
- Abstract
Loading... -
+
P14.27 - Pathogenic Genomic Alterations of CDKN2A Predict Immunotherapy Resistance in NSCLC
00:00 - 00:00 | Presenter: Stanley Gutiontov
- Abstract
Loading... -
+
P14.28 - Association Between the Type of First-Line Chemotherapy and Outcome of Second-Line Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Mihyun Kim
- Abstract
Loading... -
+
P14.29 - Toripalimab in Combination with CIK Cells in Patients with Advanced NSCLC: An Exploratory Study
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P14.32 - Predictive Value of Neutrophil-Lymphocyte Ratio on the Outcome of Patients with Advance NSCLC Treated with PD-1 Inhibition and Radiotherapy
00:00 - 00:00 | Presenter: Fen Wang
- Abstract
Loading... -
+
P14.33 - Soluble PD-L1 as Biomarker of Benefit from Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Carlo Genova
- Abstract
Loading...
-
+
P15 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Phase I)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P15.01 - AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Keegan Cooke
- Abstract
Loading... -
+
P15.02 - Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sonam Puri
- Abstract
Loading... -
+
P15.03 - A Phase 1/1b Study of Lazertinib as Monotherapy and in Combination with Amivantamab in Advanced EGFR-Mutated NSCLC
00:00 - 00:00 | Presenter: Koichi Goto
- Abstract
Loading... -
+
P15.04 - A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jonathan Riess
- Abstract
Loading... -
+
P15.06 - Safety of BMS-986012, an Anti–Fucosyl-GM1 Monoclonal Antibody Plus Platinum/Etoposide in Untreated Extensive-Stage SCLC
00:00 - 00:00 | Presenter: Luis G. Paz-Ares
- Abstract
Loading... -
+
P15.07 - Safety and Efficacy Profile of TQB-2450 Alone/with Anlotinib in Previously-Treated Advanced NSCLC: A Phase IB Single-Arm Trial
00:00 - 00:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P15.08 - Phase I Trial of in situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
00:00 - 00:00 | Presenter: Aaron Lisberg
- Abstract
Loading... -
+
P15.09 - A Promising Result of Two Therapeutic Peptides Combined with Chemotherapy in the Treatment of Advanced NSCLC.
00:00 - 00:00 | Presenter: Jiangnan Feng
- Abstract
Loading...
-
+
P16 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Novel Immunotherapeutics (Translational)
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P16.01 - The Effect of Different Dose and Sites of Irradiation on Lymphocyte Subsets in Peripheral Blood of Patients With Lung Cancer
00:00 - 00:00 | Presenter: Xiaoxia Zhu
- Abstract
Loading... -
+
P16.02 - Impact of Number and Location of Metastatic Sites on Survival in Stage IV ICI-Treated NSCLC
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P16.03 - Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients
00:00 - 00:00 | Presenter: Amanda Jane Williams Gibson
- Abstract
Loading... -
+
P16.04 - CDK4/6 Inhibitors Reverse Resistance to Anti-PD-1 Therapy in Lung Adenocarcinoma with LKB1 Deficiency Through pRB-ICAM1 Dependent Signaling
00:00 - 00:00 | Presenter: Zhong-Yi Dong
- Abstract
Loading... -
+
P16.05 - Exploratory Study of Sintilimab Intrapleural Therapy for NSCLC-Mediated Malignant Pleural Effusion
00:00 - 00:00 | Presenter: Tangfeng Lv
- Abstract
Loading... -
+
P16.06 - Exploration of Efficacy and irAEs of Pembrolizumab Plus Chemotherapy for Advanced NSCLC as 1st Line Treatment in Real World
00:00 - 00:00 | Presenter: Teng Li
- Abstract
Loading... -
+
P16.07 - Immuno-Modulatory Effects of Ceralasertib in Combination with Durvalumab in NSCLC with Progression on Anti-PD(L)1 Treatment (HUDSON)
00:00 - 00:00 | Presenter: Benjamin Besse
- Abstract
Loading...
-
+
P17 - Locoregional and Oligometastatic Disease - Biomarkers
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P17.01 - Adaptive Elastic-Net Nomogram Predicting Disease-Free Survival in Resected Stage IIIA (N2) Non–Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Chenchen Zhang
- Abstract
Loading... -
+
P17.02 - Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients – a Phase II Translational and Biomarker Study
00:00 - 00:00 | Presenter: Vilde Drageset Haakensen
- Abstract
Loading... -
+
P17.03 - Lung Adenocarcinoma with Lymph Node Metastasis: Is Ground Glass Opacity Component a Prognostic Factor?
00:00 - 00:00 | Presenter: Xiangyi Ma
- Abstract
Loading...
-
+
P18 - Locoregional and Oligometastatic Disease - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P18.01 - Prognostic Value of the LIPI in Patients with LA-NSCLC Receiving Definitive RT: A Retrospective Study of 1079 Patients
00:00 - 00:00 | Presenter: Wenji Xue
- Abstract
Loading... -
+
P18.02 - Factors Influencing Multi-Disciplinary Tumor Board Recommendations in Stage III Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Merle Ilona Ronden
- Abstract
Loading... -
+
P18.03 - Randomized Trial With BIALOE to Prevent Esophagitis in Lung Cancer Patients Treated With Concurrent Radical Chemoradiotherapy
00:00 - 00:00 | Presenter: Francesc Casas
- Abstract
Loading... -
+
P18.04 - Individualized Fraction Regimen of SBRT Patients with Non-small Cell Lung Cancer Based on Uncomplicated and Cancer-free Control Probability
00:00 - 00:00 | Presenter: AiHui Feng
- Abstract
Loading... -
+
P18.05 - Immunotherapy Beyond First-Line in NSCLC, Still An Option.
00:00 - 00:00 | Presenter: Andrea Modrego
- Abstract
Loading... -
+
P18.06 - Retrospective Epidemiological Study of Locally Advanced Non-Small Cell Lung Cancer Patients in Brazil – RELANCE (LACOG 0118)
00:00 - 00:00 | Presenter: Vladmir Claudio Cordeiro De Lima
- Abstract
Loading...
-
+
P19 - Locoregional and Oligometastatic Disease - Oligometastatic Disease
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P19.01 - Local Ablative Radiotherapy on Oligo-Progression while Continued on EGFR-TKI in Advanced NSCLC Patients: A Longer Cohort
00:00 - 00:00 | Presenter: Florence Siu Ting Mok
- Abstract
Loading... -
+
P19.02 - Association between Number of Residual Metastases and Patterns of Progression on EGFR TKI in EGFR mutated Non-Small Cell Lung Cancer.
00:00 - 00:00 | Presenter: Taichi Miyawaki
- Abstract
Loading... -
+
P19.03 - Operative Outcomes of Local Consolidation with Cytoreductive Surgery for Oncogenic-Driven Advanced NSCLC
00:00 - 00:00 | Presenter: Byung Jo Park
- Abstract
Loading... -
+
P19.04 - Effect of Local Therapy on Survival in Oligometastatic Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Yu Yang Soon
- Abstract
Loading... -
+
P19.05 - Postoperative Recurrence of Early-Stage Non-Small Cell Lung Cancer (NSCLC): Clinical Outcomes of Oligo versus Poly-recurrence Disease
00:00 - 00:00 | Presenter: Maria Aimé Giorlando
- Abstract
Loading... -
+
P19.06 - Radiosurgery followed by Tumor Treating Fields for brain metastases (1-10) from NSCLC in the phase 3 METIS trial
00:00 - 00:00 | Presenter: Minesh P. Mehta
- Abstract
Loading... -
+
P19.07 - Immune Checkpoint Inhibitors and Additional Local Treatment in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Akin Atmaca
- Abstract
Loading... -
+
P19.08 - Clinical Outcome of Local Treatment in Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Preliminary Analysis of Prospective Data
00:00 - 00:00 | Presenter: Xiaoxia Zhu
- Abstract
Loading... -
+
P19.09 - Lung Stereotatic Body Radiation Therapy: Outcomes from a Brazilian Cohort
00:00 - 00:00 | Presenter: LILIAN Faroni
- Abstract
Loading... -
+
P19.10 - Evaluation of Local Therapy for Oligoprogressive Disease in Metastatic NSCLC Patients on Immunotherapy
00:00 - 00:00 | Presenter: Nicholas Peter Giustini
- Abstract
Loading... -
+
P19.11 - Endobronchial Brachytherapy as Curative Therapy for Postoperative Intrabronchial Oligometastasis in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Atsushi Ito
- Abstract
Loading... -
+
P19.12 - Immunotherapy as Single Treatment for Brain Metastases of Non-small cell Lung Cancer: A Systematic Review and Meta-Analysis.
00:00 - 00:00 | Presenter: Viviane Teixeira Loiola de Alencar
- Abstract
Loading...
-
+
P20 - Locoregional and Oligometastatic Disease - Radiation
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P20.01 - Stereotactic Body Radiation Therapy for Residual Primary Lesions after First Line Treatment for Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Lin Zhou
- Abstract
Loading... -
+
P20.02 - To Evaluate the Efficacy and Optimal Timing of Postoperative Radiotherapy in Completely Resected stage IIIA(N2) Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Wen Feng
- Abstract
Loading... -
+
P20.03 - Impact of Radiotherapy Timing After Induction Chemotherapy on Survival of Patients With Locally Advanced Non Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Danijela Scepanovic
- Abstract
Loading... -
+
P20.04 - Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management
00:00 - 00:00 | Presenter: Sureyya Sarihan
- Abstract
Loading... -
+
P20.05 - Oesophageal Dose Predicts on Treatment Toxicity in Patients Receiving Concurrent Chemo-Radiotherapy for Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Cameron Angus Keogh
- Abstract
Loading... -
+
P20.06 - Dosimetric Comparison of the Real and Virtual Plans in Non-Small Cell Lung Cancer Patients Treated With Respiratory Motion Management
00:00 - 00:00 | Presenter: Sureyya Sarihan
- Abstract
Loading...
first
prev
